My bookmarksSign up free
Source

2009/826/EC: Commission Decision of 13 October 2009 authorising the placing on the market of a leaf extract from Lucerne ( Medicago sativa ) as novel food or novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2009) 7641)

2009/826/EC: Commission Decision of 13 October 2009 authorising the placing on the market of a leaf extract from Lucerne ( Medicago sativa ) as novel food or novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council (notified under document C(2009) 7641)

Regulation (EC) No 258/97 · Decision · 5 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Lucerne ( Medicago sativa ) protein concentrate, hereinafter called the product, as specified in the Annex may be placed on the market in the Community as a novel food ingredient to be used in food supplements.

Article 2

Open ↗

The maximum amount of protein extract from Lucerne ( Medicago sativa ) present in a portion recommended for daily consumption by the manufacturer shall be 10 g.

Article 3

Open ↗

The designation of the novel food ingredient authorised by this Decision on the labelling of the foodstuff containing it shall be ‘Lucerne ( Medicago sativa ) protein’ or ‘Alfalfa ( Medicago sativa ) protein’.

Article 4

Open ↗

This Decision is addressed to Luzerne — Recherche et Développement (L.-R.D.), Complexe agricole du Mont-Bernard, F-51000 Châlons-en-Champagne.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX SPECIFICATIONS OF PROTEIN EXTRACT FROM LUCERNE ( MEDICAGO SATIVA ) Description The Lucerne is processed within 2 hours after harvest. It is chopped and crushed. By passing through an oleaginous-type press, the Lucerne provides a fibrous residue and press juice (10 % of dry matter). The dry matter of this juice contains about 35 % of crude protein. The press juice (pH 5,8-6,2) is neutralised. Preheating and vapour injection allows coagulation of proteins associated with carotenoid and chlorophyll pigments. The protein precipitate is separated by centrifugation and thereafter dried. After adding ascorbic acid the Lucerne protein concentrate is granulated and stored in inert gas or in cold storage. Composition of the protein extract from Lucerne ( Medicago sativa ) Protein 45-60 % Fat 9-11 % Free carbohydrates (soluble fibre) 1-2 % Polysaccharides (insoluble fibre) including cellulose 11-15 % 2-3 % Minerals 8-13 % Saponins Not more than 1,4 % Isoflavones Not more than 350 mg/kg Coumestrol Not more than 100 mg/kg Phytates Not more than 200 mg/kg L-canavanine Not more than 4,5 mg/kg

Other acts of the same type
Council Decision of 20 January 2026 replacing a member of the Advisory Committee on freedom of movement for workers for ItalyCouncil Decision of 20 January 2026 replacing a member of the Advisory Committee on freedom of movement for workers for SwedenCommission Implementing Decision (EU) 2026/161 of 20 January 2026 amending the Annex to Implementing Decision (EU) 2023/2447 concerning emergency measures in relation to outbreaks of highly pathogenic avian influenza in certain Member States (notified under document C(2026) 412)Decision (EU) 2026/188 of the European Parliament and of the Council of 20 January 2026 providing macro-financial assistance to the Hashemite Kingdom of JordanCouncil Decision (EU) 2026/222 of 20 January 2026 authorising the opening of negotiations on behalf of the European Union for the conclusion of an agreement between the European Union, of the one part, and the Commonwealth of Australia, of the other part, on the participation of the Commonwealth of Australia in Union programmes and the association of the Commonwealth of Australia to Horizon Europe – the Framework Programme for Research and Innovation (2021-2027)Council Decision (EU) 2026/539 of 20 January 2026 on the position to be taken on behalf of the European Union within the Committee on Investment Facilitation established by the Sustainable Investment Facilitation Agreement between the European Union and the Republic of Angola as regards the adoption of the Rules of Procedure of the Committee on Investment FacilitationDecision of the Bureau of the European Parliament of 19 January 2026 amending the Implementing Measures for the Statute for Members of the European ParliamentCommission Implementing Decision (EU) 2026/116 of 19 January 2026 amending Commission Implementing Decision (EU) 2016/2321 on the format of the ready for recycling certificate issued in accordance with Regulation (EU) No 1257/2013 of the European Parliament and of the Council on ship recyclingCommission Implementing Decision (EU) 2026/121 of 19 January 2026 amending Implementing Decision (EU) 2016/2325 on the format of the certificate on the inventory of hazardous materials issued in accordance with Regulation (EU) No 1257/2013 of the European Parliament and of the Council on ship recyclingCouncil Decision (CFSP) 2026/122 of 16 January 2026 amending Decision (CFSP) 2024/385 establishing restrictive measures against those who support, facilitate or enable violent actions by Hamas and the Palestinian Islamic JihadCommission Implementing Decision (EU) 2026/127 of 15 January 2026 amending the Annexes to Implementing Decision (EU) 2025/1708 concerning certain emergency measures relating to infection with lumpy skin disease virus in France (notified under document C(2026) 319)Commission Implementing Decision (EU) 2026/128 of 15 January 2026 amending Implementing Decision (EU) 2025/2663 concerning certain emergency measures relating to infection with peste des petits ruminants virus in Croatia (notified under document C(2026) 320)

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next